A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called oral minoxidil can help improve hair loss in children, teens, and young adults who have survived cancer. The researchers want to see if this medication is safe and if it has any side effects. They will also check how well participants can stick to their dosing schedule and how taking minoxidil affects their overall quality of life.

To be eligible for this study, participants should be between 6 and 18 years old and must have been diagnosed with cancer before the age of 17. They should have completed their cancer treatments, such as chemotherapy or radiation, at least one year before joining the study. Additionally, they need to have ongoing hair loss related to their previous cancer treatments for more than six months. Participants will receive the oral minoxidil and will be monitored for its effects and any side effects during the trial. This is a great opportunity for young cancer survivors experiencing hair loss to explore a potential treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have been diagnosed with cancer before the age of 17.
• • They must have completed either systemic or radiation therapy (cytotoxic chemotherapy and external beam radiation therapy) for their cancer at least 1 year prior to study entry.
• • They must be between 6-18 years old at the time of enrollment.
• • They must have a clinical diagnosis of persistent or late alopecia for \>6 months and that is definitely, probably, or possibly related to prior chemotherapy and/or radiation.
• Exclusion Criteria:
• • Had a history of alopecia prior to systemic or radiation therapy for cancer, or has alopecia unrelated to cancer treatment.
• • Have scalp disorders that preclude the evaluation of alopecia, such as psoriasis
• • Has a known hypersensitivity to minoxidil
• • Concurrent use of other therapies for alopecia
• • Concurrent active anticancer therapies (cytotoxic, targeted, endocrine, immunologic)
• • History of chronic sclerotic cutaneous GvHD affecting the scalp
• • Active chronic cutaneous GvHD
• • History of orthostatic or symptomatic hypotension, syncope related to hypotension; systolic less than or equal than 100 (for adults) and 90 (for children) at screening.
• • Pregnancy.
• • Cardiovascular disease that in the opinion of the cardiologist makes the patient unsuitable for therapy
• • Blood pressure less than the 5th percentile or less than 90/50 mmHg for children 10 years or older